To address this knowledge gap, we conducted a large retrospective cohort study using data from a global federated research network to evaluate the risk of all-cause death and pancreatic adverse events in people with obesity or T2DM initiating GLP-1 RA therapy. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.